Free Trial
NASDAQ:ANNX

Annexon Q1 2023 Earnings Report

Annexon logo
$1.46 +0.03 (+2.10%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.51 +0.05 (+3.42%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.52
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annexon Announcement Details

Quarter
Q1 2023
Time
Q1 2023 Earnings Release
Conference Call Date
Monday, May 8, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Annexon's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Annexon Earnings Headlines

Something strange going on at Mar-a-Lago
A former government advisor says a $9 trillion AI breakthrough is nearing launch. It may become America’s biggest advantage in the race against China — and a handful of Musk-linked companies could benefit.
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

View Annexon Profile

More Earnings Resources from MarketBeat